Biosimilar versions of several blockbuster drugs, including AbbVie’s Humira (adalimumab), Roche’s Herceptin (trastuzumab) and Avastin (bevacizumab), and Amgen’s Neulasta (pegfilgrastim) are under review at the European Medicines Agency.
The EMA publishes a monthly table of products that are under evaluation by the agency’s scientific committee, the CHMP, although the details can change during the subsequent month as new
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?